Sab Biotherapeutics Inc (SABS)

$2.79 +0.25 (9.84%)
Market Cap 24.99M
Revenue (ttm) 1.32M
Net Income (ttm) -34.11M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,584.09%
Debt to Equity Ratio 0.00
Volume 37,000
Avg Vol 53,268
Day's Range N/A - N/A
Shares Out 9.29M
Stochastic %K 73%
Beta 0.52
Analysts Strong Sell
Price Target $11.40

Company Profile

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte glo...

Industry: Biotechnology
Sector: Healthcare
Phone: 605 679 6980
Address:
777 W 41st St., Miami Beach, United States
DDiamond_Handz
DDiamond_Handz Jul. 16 at 7:07 PM
$SABS
0 · Reply
Nicks_pics
Nicks_pics Jul. 16 at 4:50 PM
$SABS Strangely my SABS holding is my biggest paper loss and yet has been the easiest to hold long term. Pushing SAB-142 to the priority clinical trial product changed everything. I’ve been adding and quite comfortable since then.
0 · Reply
JTebow_CWS
JTebow_CWS Jul. 16 at 1:07 PM
$SABS $REGN While they work on SAB-142 for Type 1 Diabetes. Let’s not forget SAB-176 is still superior treatment for Flu. https://ir.sab.bio/static-files/ada5283c-db0e-45d5-8857-4999a1d1fd5a
1 · Reply
SwingNow
SwingNow Jul. 14 at 7:49 PM
$SABS swinging this one
0 · Reply
JTebow_CWS
JTebow_CWS Jul. 14 at 2:11 AM
$SABS https://youtu.be/DbP-aPkjVNE?si=YoAgrxOwrwuQBU1Q
0 · Reply
JTebow_CWS
JTebow_CWS Jul. 13 at 10:06 PM
$SABS This YouTube short is about TZIELD. https://youtube.com/shorts/GfUl7ro45FQ?si=-EA-ZeTdO3u-ZGRH
1 · Reply
JTebow_CWS
JTebow_CWS Jul. 13 at 2:24 AM
$SABS https://podcasts.apple.com/us/podcast/top-producer-podcast/id1571998582?i=1000641030267
0 · Reply
StockScanners
StockScanners Jul. 12 at 7:16 AM
$SABS reached 2.73
0 · Reply
JTebow_CWS
JTebow_CWS Jul. 11 at 10:17 PM
$SABS Interstates at 15:30 Like to see a cure for Type 1 Diabetes after the 27 minute mark. Ends at 34:30 https://podcasts.apple.com/us/podcast/squawk-pod/id1480890290?i=1000716855047
1 · Reply
JTebow_CWS
JTebow_CWS Jul. 11 at 9:03 AM
$SABS $REGN Excellent explanation of polyclonal antibodies. Definitely the Lord’s amazing design.
3 · Reply
Latest News on SABS
SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates

May 9, 2025, 9:00 AM EDT - 2 months ago

SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates

SAB BIO Reports Full Year 2024 Operating and Financial Results

Mar 31, 2025, 7:32 AM EDT - 3 months ago

SAB BIO Reports Full Year 2024 Operating and Financial Results

SAB BIO to Participate in Upcoming Investor Conferences

Jan 31, 2025, 7:00 AM EST - 5 months ago

SAB BIO to Participate in Upcoming Investor Conferences

Why Is SAB BIO Stock Trading Lower On Tuesday?

Jan 28, 2025, 3:40 PM EST - 6 months ago

Why Is SAB BIO Stock Trading Lower On Tuesday?

SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142

Jan 28, 2025, 7:00 AM EST - 6 months ago

SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142

SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy

Jan 23, 2025, 7:00 AM EST - 6 months ago

SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy

SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update

Nov 6, 2024, 5:05 PM EST - 9 months ago

SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update

SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference

Sep 13, 2024, 7:00 AM EDT - 10 months ago

SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference

SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting

Sep 4, 2024, 7:05 AM EDT - 11 months ago

SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting

SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates

Aug 8, 2024, 5:51 PM EDT - 1 year ago

SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates

SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes

Aug 5, 2024, 7:30 AM EDT - 1 year ago

SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes

SAB BIO Appoints Lucy To as Chief Financial Officer

Jul 31, 2024, 7:30 AM EDT - 1 year ago

SAB BIO Appoints Lucy To as Chief Financial Officer

SAb Biotherapeutics Rebrands as SAB BIO

Jun 20, 2024, 7:20 AM EDT - 1 year ago

SAb Biotherapeutics Rebrands as SAB BIO

SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions

Jun 18, 2024, 1:10 PM EDT - 1 year ago

SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions

SAB Biotherapeutics Announces Departure of Chief Financial Officer

May 30, 2024, 4:45 PM EDT - 1 year ago

SAB Biotherapeutics Announces Departure of Chief Financial Officer

FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics

May 21, 2024, 7:15 AM EDT - 1 year ago

FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics

SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates

May 20, 2024, 5:45 PM EDT - 1 year ago

SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates

SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors

May 6, 2024, 7:15 AM EDT - 1 year ago

SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors

SAB Biotherapeutics Provides SAB-142 Trial Update

Apr 16, 2024, 7:15 AM EDT - 1 year ago

SAB Biotherapeutics Provides SAB-142 Trial Update

SAB Biotherapeutics to Present at INNODIA Annual Meeting

Apr 8, 2024, 7:15 AM EDT - 1 year ago

SAB Biotherapeutics to Present at INNODIA Annual Meeting

SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference

Apr 4, 2024, 7:15 AM EDT - 1 year ago

SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference

SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

Mar 29, 2024, 7:15 AM EDT - 1 year ago

SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment

Mar 25, 2024, 10:15 AM EDT - 1 year ago

SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment

SAB Biotherapeutics to Present at the BIO CEO & Investor Conference

Feb 23, 2024, 8:00 AM EST - 1 year ago

SAB Biotherapeutics to Present at the BIO CEO & Investor Conference

SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 8, 2024, 8:00 AM EST - 1 year ago

SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

SAB Biotherapeutics Announces Executive Leadership Change

Feb 2, 2024, 7:30 AM EST - 1 year ago

SAB Biotherapeutics Announces Executive Leadership Change

SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jan 23, 2024, 5:58 PM EST - 1 year ago

SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split

Jan 2, 2024, 4:30 PM EST - 1 year ago

SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split

SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

Nov 29, 2023, 7:30 AM EST - 1 year ago

SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors

Nov 20, 2023, 7:30 AM EST - 1 year ago

SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors

SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes

Nov 14, 2023, 7:30 AM EST - 1 year ago

SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes

SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates

Nov 14, 2023, 7:15 AM EST - 1 year ago

SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates

SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference

Nov 9, 2023, 7:30 AM EST - 1 year ago

SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference

SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer

Oct 24, 2023, 7:30 AM EDT - 1 year ago

SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer

SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

Oct 19, 2023, 7:30 AM EDT - 1 year ago

SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors

Oct 5, 2023, 7:30 AM EDT - 1 year ago

SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors

SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes

Oct 2, 2023, 7:30 AM EDT - 1 year ago

SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes

SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results

Aug 21, 2023, 8:30 AM EDT - 2 years ago

SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results

SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023

Jun 21, 2023, 8:30 AM EDT - 2 years ago

SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023

SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention

May 30, 2023, 8:30 AM EDT - 2 years ago

SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention

DDiamond_Handz
DDiamond_Handz Jul. 16 at 7:07 PM
$SABS
0 · Reply
Nicks_pics
Nicks_pics Jul. 16 at 4:50 PM
$SABS Strangely my SABS holding is my biggest paper loss and yet has been the easiest to hold long term. Pushing SAB-142 to the priority clinical trial product changed everything. I’ve been adding and quite comfortable since then.
0 · Reply
JTebow_CWS
JTebow_CWS Jul. 16 at 1:07 PM
$SABS $REGN While they work on SAB-142 for Type 1 Diabetes. Let’s not forget SAB-176 is still superior treatment for Flu. https://ir.sab.bio/static-files/ada5283c-db0e-45d5-8857-4999a1d1fd5a
1 · Reply
SwingNow
SwingNow Jul. 14 at 7:49 PM
$SABS swinging this one
0 · Reply
JTebow_CWS
JTebow_CWS Jul. 14 at 2:11 AM
$SABS https://youtu.be/DbP-aPkjVNE?si=YoAgrxOwrwuQBU1Q
0 · Reply
JTebow_CWS
JTebow_CWS Jul. 13 at 10:06 PM
$SABS This YouTube short is about TZIELD. https://youtube.com/shorts/GfUl7ro45FQ?si=-EA-ZeTdO3u-ZGRH
1 · Reply
JTebow_CWS
JTebow_CWS Jul. 13 at 2:24 AM
$SABS https://podcasts.apple.com/us/podcast/top-producer-podcast/id1571998582?i=1000641030267
0 · Reply
StockScanners
StockScanners Jul. 12 at 7:16 AM
$SABS reached 2.73
0 · Reply
JTebow_CWS
JTebow_CWS Jul. 11 at 10:17 PM
$SABS Interstates at 15:30 Like to see a cure for Type 1 Diabetes after the 27 minute mark. Ends at 34:30 https://podcasts.apple.com/us/podcast/squawk-pod/id1480890290?i=1000716855047
1 · Reply
JTebow_CWS
JTebow_CWS Jul. 11 at 9:03 AM
$SABS $REGN Excellent explanation of polyclonal antibodies. Definitely the Lord’s amazing design.
3 · Reply
DDiamond_Handz
DDiamond_Handz Jul. 10 at 3:52 PM
$SABS
0 · Reply
DDiamond_Handz
DDiamond_Handz Jul. 9 at 10:00 PM
$SABS should fill all the way back to 5.00+
1 · Reply
StockScanners
StockScanners Jul. 9 at 1:57 AM
$SABS Keep watch if this holds above 2.35
0 · Reply
kadeee
kadeee Jul. 8 at 6:47 PM
$LGVN Someone wants this higher. Let's $RYDE !!! $PROK $SABS
1 · Reply
JTebow_CWS
JTebow_CWS Jul. 8 at 6:09 PM
$SABS Really the last 6 minutes. SAB is mentioned on the last 2 minutes. https://podcasts.apple.com/us/podcast/diabetech-diabetes-tech-research-news/id1685551028?i=1000716310311
0 · Reply
Nicks_pics
Nicks_pics Jul. 8 at 5:56 PM
$SABS
0 · Reply
Edok
Edok Jul. 8 at 5:08 PM
$SABS so happy to see Bullish attached to $SABS! I believe 100% in this company’s ability to create and produce Biotherapeutics that can change lives.
0 · Reply
stockboyaisle1
stockboyaisle1 Jul. 8 at 3:20 AM
$SABS anyone make any sense of the sp today?
2 · Reply
DDiamond_Handz
DDiamond_Handz Jul. 7 at 11:00 PM
$SABS
0 · Reply
Quid_Pro_Quo
Quid_Pro_Quo Jul. 7 at 4:47 PM
$SABS Something‘s cooking
1 · Reply
JTebow_CWS
JTebow_CWS Jun. 29 at 8:46 PM
$SABS $REGN potential buyout for Type 1 DM. https://youtu.be/OlRwqSbOUfo?si=vd8E_fV75VgpJ6D4
2 · Reply
JTebow_CWS
JTebow_CWS Jun. 29 at 8:45 PM
$SABS $REGN Ok. Here we go. Whoa. Dr Sam Reich MD and Mike Haller MD, University of Florida, Chief of Endocrinology interview. https://podcasts.apple.com/us/podcast/diabetech-diabetes-tech-research-and-news/id1685551028?i=1000703451728
1 · Reply